Abstract
Intravesical immunotherapy has been proven to be an effective approach for the management of carcinoma in situ and a proportion of high-grade, non-muscle invasive bladder cancers. The use of intravesical Bacillus Calmette-Guerin (BCG) has been extensively studied in this setting, allowing insight into the therapeutic cascade of immune response following BCG exposure. A number of virus-based strategies have been investigated that target tumor-specific epitopes in the hope of developing more effective and durable forms of treatment. Herein, we review the mechanistic action of vaccine therapies and report on the rationale and progress of vaccine-based strategies for the treatment of localized bladder cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Shah, J.B. and J.M. McKiernan, Novel therapeutics in the treatment of bladder cancer. Curr Opin Urol, 2004. 14(5): 287–293.
Pantuck, A.J., et al, Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother, 2004. 27(3): 240–253.
Gomella, L.G., et al, Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol, 2001. 166(4): 1291–1295.
Lam, J.S., et al, Bacillus Calmete-Guerin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol, 2003. 21(5): 354–360.
O'Donnell, M.A., Combined bacillus Calmette-Guerin and interferon use in superficial bladder cancer. Expert Rev Anticancer Ther, 2003. 3(6): 809–821.
Punnen, S.P., J.L. Chin, and M.A. Jewett, Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy. Can J Urol, 2003. 10(2): 1790–1795.
Coe, J.E. and J.D. Feldman, Extracutaneous delayed hypersensitivity, particularly in the guinea-pig bladder. Immunology, 1966. 10(2): 127–136.
Morales, A., D. Eidinger, and A.W. Bruce, Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol, 1976. 116(2): 180–183.
Lamm, D.L., et al, Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol, 1980. 124(1): 38–40.
Alexandroff, A.B., et al, BCG immunotherapy of bladder cancer: 20 years on. Lancet, 1999. 353(9165): 1689–1694.
Prescott, S., et al, Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol, 1992. 147(6): 1636–1642.
Sharma, P., et al, Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res, 2006. 12(18): 5442–5447.
Chatterjee, S.J., et al, Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol, 2004. 22(6): 1007–1013.
Fearon, E.R., et al, Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 1990. 60(3): 397–403.
Cote, R.J., et al, Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res, 1998. 58(6): 1090–1094.
Casado, E., et al, Doomed trials for promising adenoviruses: a rationale for success. J Clin Oncol, 2004. 22(6): 1162-3; author reply 1163–1164.
Sabichi, A., et al, Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol, 2006. 175(3 Pt 1): 1133–1137.
Loskog, A., et al, Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol, 2001. 166(3): 1093–1097.
Abraham, S., et al, Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res, 2006. 12(2): 353–360.
Zelinski, D.P., et al, EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res, 2001. 61(5): 2301–2306.
Cardillo, M.R., et al, Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer. J Exp Clin Cancer Res, 2000. 19(2): 225–233.
Nassar, H., et al, Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod Pathol, 2004. 17(9): 1045–1050.
Scholl, S.M., et al, Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother, 2000. 23(5): 570–580.
Gilboa, E., et al, Immunotherapy of cancer using cytokine gene-modified tumor vaccines. Semin Cancer Biol, 1994. 5(6): 409–417.
Gansbacher, B., et al, Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med, 1990. 172(4): 1217–1224.
Saito, S., et al, Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res, 1994. 54(13): 3516–3520.
Connor, J., et al, Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med, 1993. 177(4): 1127–1134.
Jaffee, E.M., et al, High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res, 1993. 53(10 Suppl): 2221–2226.
Larchian, W.A., et al, Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. Clin Cancer Res, 2000. 6(7): 2913–2920.
Siemens, D.R., et al, Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model. J Urol, 2003. 170(3): 979–984.
Loskog, A., et al, Human urinary bladder carcinomas express adenovirus attachment and internalization receptors. Gene Ther, 2002. 9(9): 547–553.
Kuball, J., et al, Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol, 2002. 20(4): 957–965.
Pagliaro, L.C., et al, Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol, 2003. 21(12): 2247–2253.
Mastrangelo, M.J., et al,Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther, 1999. 6(5): 409–422.
Okegawa, T., et al, The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res, 2001. 61(17): 6592–6600.
Mastrangelo, M.J. and E.C. Lattime, Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Cancer Gene Ther, 2002. 9(12): 1013–1021.
Mastrangelo, M.J., et al, Poxvirus vectors: orphaned and underappreciated. J Clin Invest, 2000. 105(8): 1031–1034.
Yang, A.S., C.E. Monken, and E.C. Lattime, Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen. Cancer Res, 2003.63(20): 6956–6961.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Karanikolas, N., Coleman, J. (2009). Vaccine Development. In: Lee, C., Wood, D. (eds) Bladder Cancer. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-59745-417-9_28
Download citation
DOI: https://doi.org/10.1007/978-1-59745-417-9_28
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-58829-988-8
Online ISBN: 978-1-59745-417-9
eBook Packages: MedicineMedicine (R0)